Business
TherapeuticsMD Announces Full Year 2025 Financial Results
BOCA RATON, Fla., March 30, 2026--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2025.
About this update from Therapeuticsmd, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/2e03b23179d57f83240925fd73a556b3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oyNJolCgd1YaMYHVrs_l1A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/2e03b23179d57f83240925fd73a556b3","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/RuAFlxrzZaPLHmo.eeQoag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/2e03b23179d57f83240925fd73a556b3","width":1024,"height":512}},"lazy":false},{"type":"text","content":"BOCA RATON, Fla., March 30, 2026--(BUSINESS WIRE)--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2025.","length":275,"tagName":"p"},{"type":"text","content":"Full Year 2025 Financial Results","length":32,"tagName":"p"},{"type":"text","content":"Net Loss from Continuing Operations","length":35,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net loss from continuing operations was $(0.7) million, or $(0.06) per basic and diluted common share, an improvement of $1.7 million, compared to net loss from continuing operations of $(2.3) million, or $(0.20) per basic and diluted common share, for 2024.","length":258,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":258,"olType":false},{"type":"text","content":"License Revenues from Continuing Operations","length":43,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"License revenue, primarily from the Mayne License Agreement, totaled $3.0 million during the year ended December 31, 2025, an increase of $1.3 million, or 71.6%, compared to $1.8 million in license revenue during the year ended December 31, 2024. The increase is primarily attributable to changes in sales of licensed products.","length":327,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":327,"olType":false},{"type":"text","content":"Total Operating Expenses from Continuing Operations","length":51,"tagName":"p"},{"type":"list","items":[{"val":[{"type"...